Please login to the form below

Not currently logged in
Email:
Password:

non-alcoholic steatohepatitis drugs

This page shows the latest non-alcoholic steatohepatitis drugs news and features for those working in and with pharma, biotech and healthcare.

Allergan buys two NASH drug developers in one day

Allergan buys two NASH drug developers in one day

Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH) drug developers Tobira Therapeutics and Akarna Therapeutics. ... pipeline. The acquisition puts Allergan in a race to market with

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics